Fig. 1From: Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysisOverall survival (OS) of all solid tumor patients (A), solid tumor patients who received immunotherapy in 1 L (B), and ≥ 2 L (C) metastatic settings with and without irAEBack to article page